Cas:210555-94-5 para-dodecylphenol manufacturer & supplier

Chemical Name:para-dodecylphenol

CAS.NO:210555-94-5

Synonyms:Phenol, 4-(3,5,7-trimethylnonyl)-;4-(3,5,7-Trimethylnonyl)phenol;Phenol,4-dodecyl-,branched;Phenol, 4-dodecyl-, branched;para-dodecylphenol;4-dodecylphenol, branched

Molecular Formula:C₁₈H₃₀O

Molecular Weight:262.430

HS Code:2907199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:362.6±11.0 °C at 760 mmHg

Density:0.9±0.1 g/cm3

Index of Refraction:1.497

PSA:20.23000

Exact Mass:262.229675

LogP:7.24

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Phenol, 4-(3,5,7-trimethylnonyl)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-dodecylphenol, branched physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Phenol, 4-dodecyl-, branched Use and application,4-dodecylphenol, branched technical grade,usp/ep/jp grade.

Related News: The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs. para-dodecylphenol manufacturer The survival benefit is “unprecedented” for an aging myeloma population, almost all of whom were 65 years of age or older, said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. para-dodecylphenol supplier Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells. para-dodecylphenol vendor The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs. para-dodecylphenol factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.